Monitor the special meeting vote outcome on November 10, 2026. If approved, the warrant overhang could pressure the stock as holders may sell shares acquired at $1.37. The company's obligation to hold repeated meetings if approval fails adds cost and management distraction risk.
Price Chart
Executive Summary
Dare Bioscience is holding a special meeting on November 10, 2026 to seek stockholder approval for the potential issuance of up to 8,934,345 shares of common stock upon exercise of warrants issued in an August 2026 financing. Approval is required under Nasdaq's 20% Rule because the total shares issuable (including those already issued in the registered direct offering) exceed 19.99% of pre-transaction outstanding shares. If approved, full warrant exercise would dilute existing stockholders by ~45.4% and could generate up to ~$12.4 million in gross proceeds.
Key Facts
- Special meeting on November 10, 2026 to vote on warrant exercise approval
- Warrants cover up to 8,934,345 shares (4,379,581 Series A, 4,379,581 Series B, 175,183 placement agent warrants)
- Full exercise would dilute existing stockholders by ~45.4% based on 19,669,083 shares outstanding
- Exercise prices: $1.37/common warrant, $2.1235/placement agent warrant
- Potential gross proceeds of ~$12.4 million if all warrants exercised for cash
- August 2026 financing also included 4,085,687 shares and 293,894 pre-funded warrants at $1.37/$1.3699
- Warrants not exercisable until stockholder approval obtained
- Series A warrants expire 5 years post-approval, Series B expire 2 years post-approval
- Board recommends FOR both proposals
- Morrow Sodali engaged as proxy solicitor for $10,000 fee
- Record date: September 30, 2026; 19,669,083 shares outstanding
- Law Custodial, Inc. is 5.6% stockholder; all directors and officers collectively own 3.4%
Financial Impact
Potential dilution of ~45.4% if all warrants exercised; up to ~$12.4 million gross proceeds
Risk Factors
- 45.4% dilution if all warrants exercised
- Warrant overhang could depress stock price regardless of exercise
- Repeated meeting costs if approval not obtained
- Failure may discourage future investors and impair capital access
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001493152-26-045977 |
| Document: 0001493152-26-045977-index-headers.html | 0001493152-26-045977 |
| Document: 0001493152-26-045977-index.html | 0001493152-26-045977 |
| Document: 0001493152-26-045977.txt | 0001493152-26-045977 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers